DPA promotes hBMSCs osteogenic differentiation by miR-9-5p/ERK/ALP signaling pathway

Abstract

Docosahexaenoic acid (DHA) has been reported potentiate osteogenic differentiation, while Docosapentaenoic acid (DPA), another Omega-3 fatty acid, its contribution to the osteogenic differentiation of human bone-marrow-derived mesenchymal stromal cells (hBMSCs) is not entirely elucidated. The Alizarin Red S (ARS) staining and the expression of osteogenesis-associated genes were analyzed during osteogenic induction by DPA. Then, bioinformatics analysis and dual luciferase reporter assays were investigated to confirm the interactions between miR-9-5p and alkaline phosphatase (ALP). miR-9-5p mimics / inhibitor were transfected to human hBMSCs and the osteogenic assay above was also performed. Furthermore, DPA significantly promoted the phosphorylation of ERK via miR-9-5p. PD98059, a highly specific and potent ERK1/2 inhibitor, inhibited the activation of ALP and partially reversed the role of DPA during osteogenic differentiation. These data indicated that DPA promoted osteogenic differentiation of hBMSCs potentially through miR-9-5p/ERK/ALP signaling pathway, providing a potentially useful therapeutic strategy for patients to improve bone loss.

Exploration of altered miRNA expression and function in MSC-derived extracellular vesicles in response to hydatid antigen stimulation

“…This suggests that miR-9-5p may have a representative role in the immunomodulation of hydatid disease. Previous studies have shown that miR-9-5p can promote the anti-inflammatory effects of MSCs, inhibit osteogenic differentiation and mineralization of osteoblast lineage cells, and promote osteoclastogenesis through the activation of the SIRT1/NFκB signaling pathway ( Zhang L. et al, 2021 ; Gao et al, 2022 ; He et al, 2022 ). This indicates that miR-9-5p has the potential to modulate immunosuppression and regulate the osteogenic/osteoclastic balance in hydatid disease.…”

A Novel Approach Using Reduced Graphene Oxide for the Detection of ALP and RUNX2 Osteogenic Biomarkers

“…Traditionally, the quantification of ALP and RUNX2 has relied on laborious and often expensive techniques, including enzyme-linked immunosorbent assays (ELISAs) [20,21], Western blotting [22,23], and polymerase chain reaction (PCR) [24,25]. These methods, while valuable for research, are impractical for rapid, point-of-care diagnostics or realtime monitoring of osteogenic processes.…”